期刊文献+

重组人干扰素α-2b-卡介苗对膀胱癌MB49细胞的体外作用 被引量:3

Effect of recombinant hIFN-αt-2b-BCG on mouse bladder tumor MB49 cells in vitro
原文传递
导出
摘要 目的探讨重组人干扰素α-2b-卡介苗(hIFN—α-2b—BCG)对膀胱肿瘤细胞的直接效应及其作用机制。方法采用体外实验,将重组hIFN-α-2b—BCG直接作用于小鼠膀胱癌MB-49细胞,荧光染色后,在光镜和电镜下观察细胞的变化。采用四甲基偶氮唑蓝(MTT)和流式细胞仪(FCM),检测野生型BCG和重组hIFN—α-2b—BCG对MB49细胞的影响。结果重组hIFN-α-2b—BCG与MB49细胞共培养后,光镜下见肿瘤细胞变圆,增殖速度明显减缓,部分细胞脱壁,胞浆呈大量空泡和颗粒状。透射电子显微镜下可见肿瘤细胞表面微绒毛脱落,细胞质坏死,大量空泡,细胞表面有出泡现象。吖啶橙染色后,在荧光显微镜下可见肿瘤细胞聚集成团状的细胞球体,胞突消失,凋亡小体出现。Hoechst33258染色后,可见大量肿瘤细胞呈明亮的蓝色荧光。MTT测定结果显示,随共培养时间延长,重组hIFN—α-2b—BCG可不同程度抑制肿瘤细胞的生长,抑制率高于野生BCG。FCM检测结果显示,24h后野生型BCG诱导凋亡率为10.8%,重组hIFN—α-2b—BCG诱导凋亡率为19.7%;48h后野生型BCG诱导凋亡率为20.9%,重组hIFN—α-2b—BCG诱导凋亡率为46.6%。两者比较,差异有统计学意义(P〈0.01)。重组hIFN-α-2b—BCG上调MB49细胞MHC—I表达,具有时间依赖性,且上调比例明显高于野生型BCG(P〈0.01)。结论重组hIFN—α-2b—BCG成功诱导肿瘤细胞凋亡,有更高的调节免疫原性、抗肿瘤作用和细胞毒性。 Objective To investigate the antitumor effect of recombinant IFN-α-2b-BCG on mouse bladder cancer MB49 cells in vitro, and to explore its antitumor mechanisms. Methods MB49 cells were coultured with recombinant BCG or wild BCG, and than were examined by light and transmission electron microscopy. The cell growth was assessed by MTT assay, and apoptosis rate and MHC-I of the MB49 cells was detected by flow cytometry using AO and Hoechst33258 fluorescence immunostaining. Results The hIFN-α-2b-BCG-treated tumor cells showed slow growth, detachment of some cells, and various degree of degeneration. Light microscopy revealed organelle disorganization, chromatin aggregation, nuclear pyknosis, and cytolysis in some cells. Cellular membrane bulged and some bubbles were seen under fluorescence microscope using AO staining. Hoeehst33258 assay also depicted frequent apoptosis in the tumor cells. The MTT assay showed that rBCG more actively than the wild BCG inhibited the proliferation of MB49 cells. The apoptosis rate of the recombinant BCG group was 19.7% and 46.6% at the time point of 24 h and 48 h, respectively, significantly higher than 10.8% and 20.9% , respectively, in the wild BCG group. The results of flow cytometry indicated that both types of BCG enhanced the expression of MHC-I in the MB49 cells, but more effective in the recombinant BCG group. Conclusion The recombinant hIFN-α-2b-BCG has more strong immuno-modulatory properties, anti-tumor effect on MB49 cells and induces apparent cytotoxicity in the bladder cancer cells in vitro.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2010年第4期244-248,共5页 Chinese Journal of Oncology
基金 国家自然科学基金(30872587) 天津市科技支撑计划重大项目(07ZCKFSH03200) 国家科技部“十一五”重大专项新药创建课题(2009ZX09103-699)
关键词 膀胱肿瘤 重组卡介苗 人干扰素Α-2B 凋亡 Urinary bladder neoplasms Recombinant BCG vaccine IFN-α-2b Apoptosis
  • 相关文献

参考文献9

  • 1刘春雨,韩瑞发,马腾骧,畅继武,韩育植,隋志芳.phIFN-α-2B穿梭质粒在卡介苗中的表达[J].中华泌尿外科杂志,2006,27(S1):12-14. 被引量:8
  • 2Rajala P,Kaasinen E,Rintala E,et al.Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferonalpha.Urol Res,1992,20:215-217.
  • 3刘尚莹,曹晓明,武学清,胡佩胜.α-2b干扰素膀胱灌注预防表浅性膀胱肿瘤术后复发[J].中华肿瘤杂志,2000,22(6):522-522. 被引量:6
  • 4Moriwaki Y,Begum NA,Kobayashi M,et al.Mycobacterium bovis Bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein,SIMPLE,that bridges the missing link between lipopolysaccharide and p53-inducible gene,LITAF(PIG7),and estrogen-inducible gene,EET-1.J Biol Chem,2001,276:23065-23076.
  • 5Ryll R,Watanabe K,Fujiwara N,et al.Mycobacterial cord factor,but not sulfolipid,causes depletion of NKT celts and upregulation of CD1d1 on murine macrophages.Microbes Infect,2001,3:611-619.
  • 6O'Donnell MA,Luo Y,Chen X,et al.Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin.J Immunol,1999,163:4246-4252.
  • 7张彩,田志刚,侯桂华,张建华,王郡甫,孙汭.肿瘤细胞HLAⅠ类分子表达对NK抗性的影响及IFN-γ的调节作用[J].中华肿瘤杂志,2001,23(5):369-372. 被引量:16
  • 8Shankaran V,Ikeda H,Bruce AT,et al.IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.Nature,2001,410:1107-1111.
  • 9D'Orazio SE,Halme DG,Ploegh HL,et al.Class Ⅰa MHC-deficient BALB/c mice generate CD8 + T cell-mediated protective immunity against Listena monocytogenes infection.J Immunol,2003,171:291-298.

二级参考文献6

共引文献27

同被引文献31

  • 1杨阳,于学炜,韩洪海.吡柔比星膀胱粘膜下注射加膀胱灌注预防浅表性膀胱肿瘤术后复发的临床效果[J].国际泌尿系统杂志,2006,26(3):291-292. 被引量:3
  • 2Mochizuki Y, Matsushima E, Omura K. Perioperative assessment of psychological state and quality of life of head and neck cancer patients undergoing surgery[J]. Int J Oral Maxillofac Surg. 2009,38(2) :151-159.
  • 3Svatek RS, Herman MP, Lotan Y, et al. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer[J]. Cancer, 2006, 106(8): 1701-1707.
  • 4Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update[J]. Eur Urol, 2011, $9(6): 997-1008.
  • 5Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu~rin: multivariate analysis of data from four randomized CUETO trials[J]. Eur Urol, 2008, 53(S): 992-1001.
  • 6Guo CL, Yang XH, Cheng'vV, et al. Expression of Fas/FasL in CD8+ T and CDJ+ FoxpJ+ Treg cells--elationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients[J]. Asian PacJ Cancer Prey, 2014, 1S(6): 2613-2618.
  • 7Dai XL, Zhou SL, Q iu J, et al. Correlated expression of Fas, NF- kappaB, and VEGF-C in infiltrating ductal carcinoma of the breast[J]. EurJ Gynaecol Oncol, 2012, 33(6): 633-639.
  • 8Codony-Servat J, Garcia-Albeniz X, Pericay C, et al. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patientswith advanced colorectal cancer[J]. Med Oncol, 2013, 30(1): 428.
  • 9Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer[J]. J Urol, 1998, 160(2): 571-$76.
  • 10Perabo FG, Mattes RH, Wirger A, et al. Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo[J]. Urol Oncol, 2001, 6(4): 163- 169.

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部